ArticleClinical journal of the American Society of Nephrology : CJASN2014
Comparison of mortality of ESRD patients with lupus by initial dialysis modality.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Peritoneal dialysis versus haemodialysis for people commencing dialysis.The Cochrane database of systematic reviews · 2024Pooled it
- Propensity score matched mortality comparisons of peritoneal and in-centre haemodialysis: systematic review and meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020Pooled it
- Pooled it
- Pooled it
- Outcome of polycystic kidney disease patients on peritoneal dialysis: Systematic review of literature and meta-analysis.PloS one · 2018Pooled it
- Peritoneal dialysis in lupus nephritis: comparative outcomes vs. hemodialysis, risk stratification, and modality selection framework.Renal failure · 2026Review
- Renal Replacement Therapy in Lupus Nephritis-Related End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.ACR open rheumatology · 2025Review
- Systemic Lupus Erythematosus in Hemodialysis: Survival Comparison and Mortality-Related Factors.Medicina (Kaunas, Lithuania) · 2025Article
- Evidence based treatment for lupus nephritis: present perspectives and challenges.Frontiers in nephrology · 2024Review
- Patient Survival Between Hemodialysis and Peritoneal Dialysis Among End-Stage Renal Disease Patients Secondary to Myeloperoxidase-ANCA-Associated Vasculitis.Frontiers in medicine · 2021Article
- Differences in initial treatment modality for end-stage renal disease among glomerulonephritis subtypes in the USA.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesLittle is known regarding whether mortality among ESRD patients with SLE differs between those initiating with peritoneal dialysis (PD) versus hemodialysis (HD). This study compared the mortality risk of ESRD patients with SLE initiating with PD versus HD after matching their baseline sociodemographic and clinical factors. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Of 11,023 ESRD patients with SLE initiating dialysis with PD or HD between 1995 and 2006 with complete records in the US Renal Data System, 1352 pairs were matched on 13 predictors utilizing a predicted probability of group membership into the PD group using propensity score matching. The primary outcome was overall mortality. Secondary outcomes were cardiovascular-related and infection-related mortality. Outcomes were compared between groups with survival statistics. The period of observation ended on December 31, 2009. The median follow-up was 3 years.
resultsMatched pairs were predominantly women (86%) with a median age of 39 years. Matched pairs had a balance (P ≥ 0.05) of all baseline factors. Matched pairs had a similar risk of overall mortality (hazard ratio, 0.96 [95% confidence interval, 0.82 to 1.13]; mortality, 21.4% [290 to 1352] versus 22.5% [304 to 1352] for PD versus HD) within the first 3 years of observation. Matched pairs also had similar cardiovascular-related mortality (10.5% versus 9.5% for PD versus HD) and infection-related mortality (3% versus 4.4% for PD versus HD).
conclusionsIn ESRD patients with SLE, the mortality was similar among those initiating with PD versus HD after predictors were matched between groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.